Unless I'm mistaken this confirms that a statistically significant induced immune response in a Phase 2 clinical trial setting.
I appreciate Invion doesn't have a licence for the prostate cancer indication, but this is another pretty compelling data point, in the clinic!
Feels like IVX should make an announcement around this, seems pretty market sensitive info to me IMO
@steini
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.6¢ |
Change
-0.004(4.00%) |
Mkt cap ! $8.199M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.6¢ | $5.005K | 50.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75868 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 278199 | 3 |
View Market Depth
| Last trade - 15.03pm 31/07/2025 (20 minute delay) ? |
| IVX (ASX) Chart |